Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

11/12/24 9:50:15 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BEAM alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.6 BEAM THERAPEUTICS INC COMMON STOCK Cusip #07373V105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #07373V105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,397,372 Item 6: 0 Item 7: 6,401,146 Item 8: 0 Item 9: 6,401,146 Item 11: 7.766% Item 12: HC Cusip #07373V105 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 6,401,146 Item 8: 0 Item 9: 6,401,146 Item 11: 7.766% Item 12: IN Item 1(a). Name of Issuer: BEAM THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 26 Landsdowne Street Cambridge, MA 02139 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 07373V105 Item 3. Not Applicable Item 4. Ownership (a) Amount Beneficially Owned: 6,401,146 (b) Percent of Class: 7.766% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 6,401,146 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of BEAM THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of BEAM THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Crosby Advisors LLC N/A FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK IMPRESA MANAGEMENT LLC IA Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of BEAM THERAPEUTICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $BEAM alert in real time by email

Recent Analyst Ratings for

$BEAM

Date	Price Target	Rating	Analyst
3/28/2025	$42.00	Neutral → Buy	BofA Securities
3/10/2025	$40.00	Sector Perform → Sector Outperform	Scotiabank
1/29/2025		Neutral → Overweight	Cantor Fitzgerald
11/6/2024	$27.00 → $39.00	Market Perform → Outperform	Leerink Partners
10/16/2024		Sector Outperform	Scotiabank
7/23/2024	$80.00	Buy	H.C. Wainwright
1/29/2024	$38.00 → $40.00	Neutral → Overweight	JP Morgan
12/15/2023	$35.00	Buy → Neutral	BofA Securities

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

11/12/24 9:50:15 AM ET

$BEAM

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BEAM alert in real time by email

Recent Analyst Ratings for

$BEAM

Date	Price Target	Rating	Analyst
3/28/2025	$42.00	Neutral → Buy	BofA Securities
3/10/2025	$40.00	Sector Perform → Sector Outperform	Scotiabank
1/29/2025		Neutral → Overweight	Cantor Fitzgerald
11/6/2024	$27.00 → $39.00	Market Perform → Outperform	Leerink Partners
10/16/2024		Sector Outperform	Scotiabank
7/23/2024	$80.00	Buy	H.C. Wainwright
1/29/2024	$38.00 → $40.00	Neutral → Overweight	JP Morgan
12/15/2023	$35.00	Buy → Neutral	BofA Securities

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for
$BEAM

Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for
$BEAM

$BEAM
Press Releases

Fastest customizable press release news feed in the world

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

$BEAM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Simon Amy sold $23,962 worth of shares (1,250 units at $19.17), decreasing direct ownership by 2% to 64,864 units (SEC Form 4)

SEC Form 4 filed by Director Walsh Kathleen E

SEC Form 4 filed by Director Shaw Christi

$BEAM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Beam Therapeutics upgraded by BofA Securities with a new price target

Beam Therapeutics upgraded by Scotiabank with a new price target

Beam Therapeutics upgraded by Cantor Fitzgerald

$BEAM
SEC Filings

Beam Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

Beam Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Amendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.

$BEAM
Financials

Live finance-specific insights

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

$BEAM
Large Ownership Changes

This live feed shows all institutional transactions in real time.